MARKET

BPMC

BPMC

Blueprint
NASDAQ

Real-time Quotes | Nasdaq Last Sale

60.39
+3.30
+5.78%
Closed 17:10 04/02 EDT
OPEN
56.55
PREV CLOSE
57.09
HIGH
60.50
LOW
56.09
VOLUME
544.09K
TURNOVER
--
52 WEEK HIGH
102.98
52 WEEK LOW
43.29
MARKET CAP
3.26B
P/E (TTM)
-8.2756
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BPMC stock price target is 104.64 with a high estimate of 130.00 and a low estimate of 70.00.

EPS

BPMC News

More
  • Blueprint's Avapritinib Shows Promise For Indolent Systemic Mastocytosis
  • Seeking Alpha - Article · 13h ago
  • Blueprint Medicines Announces the Achievement of Key Portfolio Milestones
  • PR Newswire · 1d ago
  • Blueprint Medicines' pralsetinib shows positive action in RET-altered thyroid cancer
  • Seeking Alpha - Article · 1d ago
  • XBI: Biotech ETF Expected To Outperform During And After The Coronavirus Pandemic
  • Seeking Alpha - Article · 2d ago

Industry

Biotechnology & Medical Research
+3.33%
Pharmaceuticals & Medical Research
+2.79%

Hot Stocks

Symbol
Price
%Change

About BPMC

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.
More

Webull offers kinds of Blueprint Medicines Corp stock information, including NASDAQ:BPMC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BPMC stock news, and many more online research tools to help you make informed decisions.